Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Amy Schrader"'
Autor:
Mark Lebwohl, Bruce Strober, Amy Schrader, Alvin H. Li, Thomas Eckmann, Baojin Zhu, William N. Malatestinic, Julie Birt, Meghan Feely, Andrew Blauvelt
Publikováno v:
Drugs - Real World Outcomes, Vol 11, Iss 3, Pp 451-464 (2024)
Abstract Background Prior work showed that patients from the CorEvitas Psoriasis Registry who had previously failed a prior biologic and then initiated ixekizumab demonstrated improvements in disease severity and patient-reported outcomes after 6 mon
Externí odkaz:
https://doaj.org/article/5609bda68fd54de38cb6383ba4e84d38
Autor:
Leslie R. Harrold, Keith Wittstock, Sheila Kelly, Xue Han, Joe Zhuo, Amy Schrader, Nicole Middaugh, Page C. Moore, Vadim Khaychuk
Publikováno v:
Advances in Rheumatology, Vol 64, Iss 1, Pp 1-11 (2024)
Abstract Background The HLA-DRB1 shared epitope (SE) is a risk factor for the development of rheumatoid arthritis (RA) and the production of anti-citrullinated protein antibodies (ACPAs) in RA patients. Our objective was to examine the real-world eff
Externí odkaz:
https://doaj.org/article/fe935ce0ec0c4b219778878a6c299874
Autor:
Leslie R. Harrold, Patrick Zueger, W. Benjamin Nowell, Taylor Blachley, Amy Schrader, Paul R. Lakin, David Curtis, Laura Stradford, Shilpa Venkatachalam, Namita Tundia, Pankaj A. Patel
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 6, Pp 1519-1533 (2023)
Abstract Introduction The impact of upadacitinib on rheumatoid arthritis (RA) symptoms was evaluated during the first 12 weeks of treatment via patient-reported outcomes (PROs) using a mobile health application (app). Methods Participating rheumatolo
Externí odkaz:
https://doaj.org/article/dd8856bcc29541ef9868140fa069a7a6
Autor:
Jonathan I. Silverberg, Evangeline Pierce, Meghan Feely, Amber Reck Atwater, Amy Schrader, Eric A. Jones, Swapna S. Dave, Eric L. Simpson
Publikováno v:
Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)
Background Real-world data on the effectiveness of systemic therapy in atopic dermatitis (AD) are limited. Methods Adult patients with AD in the CorEvitas AD registry (2020–2021) who received systemic therapies for 4–12 months prior to enrollment
Externí odkaz:
https://doaj.org/article/4a0bdb052c314f0197e45f678d872931
Autor:
Gohar Azhar, Sakeena Raza, Amanda Pangle, Kellie Coleman, Amanda Dawson, Amy Schrader, Robert R. Wolfe, Jeanne Y. Wei
Publikováno v:
Gerontology and Geriatric Medicine, Vol 6 (2020)
Approximately half of heart failure patients in the US have heart failure with preserved ejection fraction (HFpEF). HFpEF impairs physical performance and thus reduces quality of life. Increasing dietary protein intake can increase lean body mass and
Externí odkaz:
https://doaj.org/article/0caa3bf9c764490e862def35fdd29f61
Autor:
Joshua Bryson, Sheng Gao, Xue Han, Joel M. Kremer, Leslie R. Harrold, Tanya Sommers, Sabrina Rebello, T. Lehman, Amy Schrader, Joe Zhuo, Dimitrios A. Pappas
Publikováno v:
Rheumatology and Therapy
Introduction Anti-cyclic citrullinated peptide (anti-CCP) antibodies are associated with poor prognosis in patients with rheumatoid arthritis (RA). Previous data from randomized controlled trials and clinical practice have shown anti-CCP-positive (+)
Autor:
Jashin J. Wu, Robert R. McLean, Carol J. Etzel, Wendell C. Valdecantos, Amy Schrader, Rakesh K. Singh
Publikováno v:
Journal of the American Academy of Dermatology. 84:1715-1717
Autor:
Amy Schrader, Robert R. Wolfe, Jeanne Y. Wei, Sakeena Raza, Kellie S. Coleman, Amanda M. Dawson, Amanda K. Pangle, Gohar Azhar
Publikováno v:
Gerontology and Geriatric Medicine, Vol 6 (2020)
Gerontology and Geriatric Medicine
Gerontology and Geriatric Medicine
Approximately half of heart failure patients in the US have heart failure with preserved ejection fraction (HFpEF). HFpEF impairs physical performance and thus reduces quality of life. Increasing dietary protein intake can increase lean body mass and